VIVOBAREFOOT Primus Trail FG 3.5 Womens

Marsoni

M251S

$165.00

Get it in 3 business days with 1 day shipping. Friday, May 29

VIVOBAREFOOT Primus Trail FG 3.5 WomensSHOP USA SHOP UK Use code at checkout: BAREFOOTGURU15 Copy Code Reconnect with Nature: Hit the trails and embrace the wild with the Primus Trail 3. 5 FG. These lightweight, durable, and flexible trail running trainers are designed to help you feel the earth beneath your feet. Key Features: Firm Ground Outsole: Crafted from a sticky rubber compound for superior grip and durability. Minimalist Design: 3mm base and 2. 5mm lugs provide exceptional

Easy Shipping

Quick Dispatch:

Your VIVOBAREFOOT Primus Trail FG 3.5 Womens orders ship within 1-2 business days.

Delivery Options:

Standard: 3-7 business days
Fast: 2-3 business days
Express: 1-2 business days

Order Tracking:

You'll receive a tracking link by email once your VIVOBAREFOOT Primus Trail FG 3.5 Womens ships.

Need Help?
Questions about VIVOBAREFOOT Primus Trail FG 3.5 Womens, sizing, or delivery? We're just an email away.

Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for VIVOBAREFOOT Primus Trail FG 3.5 Womens in your area.

Get Shipping Estimates

Country Zip/Postal Code

Exchange/Return Notes

We offer a 30-day return/exchange service after receiving.
Final sale items are not eligible for returns or exchanges.
To process your return/exchange, please contact us at [email protected]
Please click here for more details>>> Return & Exchange Policy

DURING THIS WINTER SKIN PROBLEMS WERE PRESENT SO I TRIED THIS ITEM, AT FIRST I NOTICED THAT IT MADE MY SKIN FEEL REALLY DRY BUT IT DID CALM MY SKIN DOWN TO THE POINT WHERE THE ISSUES, WHICH WERE BECOMING INTENSE, JUST DISAPPEARED AFTER I USED IT 2-3 TIMES EVEN ON MY FACE, SO PERHAPS DRYNESS IS WHAT ENDED MY SKIN ISSUES (PSORIASIS) I HAVE EXPERIENCED IN THE PAST USING OILS AND CREAMS WHICH HAVE MADE MY ISSUES WORSE SOOOOOO THIS ITEM WAS A SUCCESS FOR ME.

WAS THIS REVIEW HELPFUL?YesReportShare

Reviewed in the United States on February 3, 2026